In vitro to in vivo extrapolation for trichloroethylene metabolism in humans

Toxicology and Applied Pharmacology

Volumn 152, Issue 2, 1998, Pages 376-387

  Lipscomb, John C ^a   Fisher, Jeffrey W ^a   Confer, Patricia D ^b   Byczkowski, Janusz Z ^c  

^a AIR FORCE RESEARCH LABORATORY   (United States)

^b SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^c ALION SCIENCE AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; CYTOCHROME P450; GLUCOSE 6 PHOSPHATASE; TRICHLOROETHYLENE;

ALCOHOL METABOLISM; ARTICLE; CELL DENSITY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; PROTEIN CONTENT; XENOBIOTIC METABOLISM;

EID: 0032191413     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1998.8485     Document Type: Article

References (52)

1. Abbas R., Fisher J. W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharmacol. 147:1997;15-30.
2. Abbas R. R., Seckel C. S., Kidney J. K., Fisher J. W. Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice. Drug Metab. Dispos. 24:1996;1340-1346.
3. Allen B. C., Fisher J. W. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal. 13:1993;71-85.
4. Andersen M. E., Clewell H. J. III, Gargas M. L., Smith F. A., Reitz R. H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87:1987;185-205.
5. Arias I. M., Popper H., Schachter D., Shafritz D. A. The Liver: Biology and Pathobiology. 1982;Raven Press, New York.
6. Barton H. A., Flemming C. D., Lipscomb J. C. Evaluating human variability in chemical risk assessment: Hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. Toxicology. 110:1996;271-287.
7. Billings R. E., McMahon R. E., Ashmore J., Wagle S. R. The metabolism of drugs in isolated hepatocytes: A comparison within vivo. Drug Metab. Dispos. 5:1977;518-526.
8. Carlile D. J., Zomorodi K., Houston J. B. Scaling factors to relate metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: Studies with induced livers involving diazepam. Drug Metab. Dispos. 25:1997;903-911.
9. Carlson G. P. Enhancement of the hepatotoxicity of trichloroethylene by inducers of drug metabolism. Res. Comm. Chem. Pathol. Pharmacol. 7:1974;637-640.
10. Chenery R. J., Keogh J. P., Rath L. C., McWilliams P. In vitro-in vivo. In Vitro Toxicology: Mechanisms and New Technology. 1991;Mary Ann Leibert, New York. p. 135-143.
11. Daniel F. B., DeAngelo A. B., Stober J. A., Olson G. R., Page N. R. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam. Appl. Toxicol. 19:1992;159-168.
12. DeAngelo A. B., Daniel F. B., McMillan L., Wernsing P., Savage R. E. Jr. Species and strain sensitivity to the induction of peroxisome proliferation by chloroacetic acids. Toxicol. Appl. Pharmacol. 101:1989;285-298.
13. DeAngelo A. B., Daniel F. B., Stober J. A., Olson G. R. The carcinogenicity of dichloroacetic acid in the male B6C3F1 mouse. Fundam. Appl. Toxicol. 16:1991;337-347.
14. Dorko K., Freeswick P. D., Bartoli F., Cicalese L., Bardsley B. A., Tzakis A., Nussler A. K. A new technique for isolating and culturing human hepatocytes from whole or split livers not used for transplantation. Cell Transplant. 3:1994;387-395.
15. el Masri H. A., Constan A. A., Ramsdell H. S., Yang R. S. Physiologically based pharmacodynamic modeling of an interaction threshold between trichloroethylene and 1,1-dichloroethylene in Fischer 344 rats. Toxicol. Appl. Pharmacol. 121:1996;124-132.
16. Evans M. V., Andersen M. E. Sensitivity analysis and the design of gas uptake inhalation studies. Inhalation Toxicol. 7:1995;1075-1094.
17. Fisher J. W., Gargas M. L., Allen B. C., Andersen M. E. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol. Appl. Pharmacol. 109:1991;183-195.
18. Fisher J. W., Mahle D. A., Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol. Appl. Pharmacol. 1998.
19. Guengerich F. P. Analysis and characterization of enzymes. Hayes A. W. Principles and Methods of Toxicology. 1989;777-814 Raven Press, New York.
20. Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179.
21. Herren-Freund S. L., Periera M. A., Khoury M. D., Olson G. The carcinogenicity of trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid, in mouse liver. Toxicol. Appl. Pharmacol. 90:1987;183-189.
22. Houston J. B. Utility of in vitro drug metabolism data in predictingin vivo. Biochem. Pharmacol. 47:1994;1469-1479.
23. Houston J. B., Carlile D. J. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab. Rev. 29:1997;891-922.
24. Ikeda M., Miyake Y., Ogata M., Ohmori S. Metabolism of trichloroethylene. Biochem. Pharmacol. 29:1980;2983-2992.
25. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C. E., Tyson C. A., Sugiyama Y. Prediction ofin vivoin vitro. Pharmacol. Ther. 73:1997;147-171.
26. Kedderis G. L., Carfagna M. A., Held S. D., Batra R., Murphy J. E., Gragas M. L. Kinetic analysis of furan biotransformation by F-344 ratsin vivoin vitro. Toxicol. Appl. Pharmacol. 123:1993;274-282.
27. Kedderis G. L., Held S. D. Prediction of furan pharmacokinetics from hepatocyte studies: Comparison of bioactivation and hepatocyte dosimetry in rats, mice and humans. Toxicol. Appl. Pharmacol. 140:1996;124-130.
28. Knadle S. A., Green C. E., Baugh M., Vidensek M., Short S. M., Partos X., Tyson C. A. Trichloroethylene biotransformation in human and rat primary hepatocytes. Toxicol. In Vitro. 4:1990;537-541.
29. Larson J. L., Bull R. J. Metabolism and lipoperoxidative activity of trichloroacetate and dichloroacetate in rats and mice. Toxicol. Appl. Pharmacol. 115:1992;268-277.
30. Leibman K. H. Metabolism of trichloroethylene in liver microsomes. II. Identification of the reaction product as chloral hydrate. Mol. Pharmacol. 1:1965;239-246.
31. Lin J. H., Hayashi M., Awazu S., Hanano M. Correlation betweenin vitroin vivo. J. Pharmacokinet. Biopharm. 6:1978;327-337.
32. Lin J. H., Sugiyama Y., Awazu S., Hanano M. Kinetic studies on the dethylation of ethoxybenzamide: A comparative study with isolated hepatocytes and liver microsomes of rat. Biochem. Pharmacol. 29:1980;2825-2830.
33. Lin J. H., Sugiyama Y., Awazu S., Hanano M. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro. J. Pharmacokinet. Biopharm. 10:1982;649-661.
34. Lipscomb J. C., Garrett C. M., Snawder J. E. Cytochrome P450 dependent metabolism of trichloroethylene: Interindividual differences in humans. Toxicol. Appl. Pharmacol. 142:1997;311-318.
35. Lipscomb J. C., Garrett C. M., Snawder J. E. Use of kinetic and mechanistic data in species extrapolation of bioactivation: Cytochrome P-450 dependent trichloroethylene metabolism at occupationally relevant concentrations. J. Occup. Health. 40:1998;110-117.
36. Maiorino R. M., Gandolfi A. J., Sipes I. G. Gas chromatographic method for the halothane metabolites, trifluoroacetic acid and bromide, in biological fluids. Anal. Tox. 4:1980;250-254.
37. Matthew D. E., Houston J. B. Drug metabolizing capacityin vitroin vivo. Biochem. Pharmacol. 40:1990a;743-749.
38. Matthew D. E., Houston J. B. Drug metabolizing capacityin vitroin vivo. Biochem. Pharmacol. 40:1990b;751-758.
39. Advanced Continuous Simulation Language (ACSL) Reference Manual. 1993;MGA Inc. Concord.
40. Muller G., Spassovski M., Henschler D. Metabolism of trichloroethylene in man. II Pharmacokinetics of the metabolites. Arch. Toxicol. 32:1974;283-295.
41. Muller G., Spassovski M., Henschler D. Metabolism of trichloroethylene in man. III Interaction of trichloroethylene and ethanol. Arch. Toxicol. 33:1975;173-189.
42. Nakajima T., Okino T., Okuyama S., Kaneko T., Yonekura I., Sato A. Ethanol-induced enhancement of trichloroethylene metabolism and hepatotoxicity: Difference from the effect of phenobarbital. Toxicol. Appl. Pharmacol. 94:1988;227-237.
43. Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
44. Opdam J. J. G. Intra- and interindividual variability in the kinetics of a poorly and highly metabolizing solvent. Br. J. Ind. Med. 46:1989;831-845.
45. 3. Toxicol. Appl. Pharmacol. 139:1996;49-61.
46. Reitz R. H., Gargas M. L., Mendrala A. L., Schumann A. M. In vivoin vitro. Toxicol. Appl. Pharmacol. 136:1996;289-306.
47. Reitz R. H., Mendrala A. L., Guengerich P. F. In vitro. Toxicol. Appl. Pharmacol. 97:1989;230-246.
48. Sato A., Nakajima T. A vial-equilibration method to evaluate the drug-metabolizing enzyme activity for volatile hydrocarbons. Toxicol. Appl. Pharmacol. 47:1979;41-46.
49. Seglan P. O. Preparation of rat liver cells. III. Enzymatic requirements for tissue dispersion. Exp. Cell. Res. 82:1973;391-398.
50. Simon T. W. Combining physiologically based pharmacokinetic modeling with Monte Carlo simulation to derive an acute inhalation guidance value for trichloroethylene. Regul. Toxicol. Pharmacol. 26:1997;257-270.
51. Stewart D. J., Inaba T. N-Demethylation of aminopyrinein vivo. Biochem. Pharmacol. 28:1979;461-464.
52. Strom S. C., Pisarov L. A., Dorko K., Thompson M. A., Scheutz J. D., Scheutz E. G. Use of human hepatocytes to study P450 gene induction. Methods Enzymol. 272:1996;388-401.